Is enasidenib a targeted drug?

Ensidipine (enasidenib) is a targeted drug targeting IDH2 mutations and is used to treat patients with relapsed or refractory acute myeloid leukemia (AML). Ensidipine is relatively optimistic in the treatment of leukemia.

Ensidipinecan cause a condition called differentiation syndrome, which affects blood cells and can be fatal if left untreated. This may occur anywhere from 10 days to 5 months after you start taking ensidipine. When taking ensidipine, follow all instructions on the prescription label and read all medication guides or inserts and take the medication exactly as directed. Drink plenty of fluids while takingensidipine. Take ensidipine at the same time every day with or without food Do not crush, chew, or break ensidipine. Swallow the whole tablet when taking it. If you vomit soon after taking Encedipine, do not take another dose and take your next dose as planned. Frequent medical tests may be needed and depending on the results, treatment may be delayed.

Store at room temperature, away from moisture and heat, Keep tablets in their original container in a jar with a hygroscopic preservative. A negative pregnancy test may be necessary before starting this treatment. Both men and women who use ensidipine should use birth control to prevent pregnancy. Ensidipine may harm an unborn baby if the mother or father is using this drug. Continue using birth control pills for at least 2 months after your last dose, and tell your doctor right away if you become pregnant. Do not breastfeed while taking this medicine, and at least2 months after your last injection. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.